Matches in SemOpenAlex for { <https://semopenalex.org/work/W4255231617> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4255231617 endingPage "1678" @default.
- W4255231617 startingPage "1671" @default.
- W4255231617 abstract "BACKGROUND A combination regimen of ifosfamide, paclitaxel, and cisplatin (ITP), recycled every 4 weeks, was reported in the treatment of previously untreated patients with advanced transitional cell carcinoma (TCC). This study sought to examine ITP at 3-week intervals to assess its feasibility and toxicity, compare the results for different schedules, and assess the impact of prognostic factors and postchemotherapy surgery on outcome. METHODS ITP (ifosfamide 1.5 g/m2 daily for 3 days, paclitaxel 200 mg/m2 over 3 hours, and cisplatin 70mg/m2 on Day 1) was administered to patients with metastatic or unresectable TCC and was recycled every 4 weeks (for 30 patients) or 3 weeks (for 15 patients). Granulocyte-colony stimulating factor was given during each cycle. RESULTS Thirty of 44 assessable patients (68%; 95% confidence interval, 52–81%) demonstrated a major response (10 complete responses [23%], 20 partial [45%]), with durations of response ranging from 4 to 36 months. At a median follow-up of 28 months, the median survival was 20 months. Eleven patients (25%) were disease free at last follow-up. Overall toxicity for the 15 patients whose treatment was recycled at 3 weeks was similar to that for patients treated every 4 weeks. Hematologic toxicity included anemia, thrombocytopenia, and febrile neutropenia. Febrile neutropenia was observed in 7 patients (16%) and in 3.3% of cycles of therapy. No Grade 4 nonhematologic toxicity was observed. Grade 3 nonhematologic toxicity included alopecia, renal insufficiency (11%), and neuropathy (9%). CONCLUSIONS ITP is an active, well-tolerated regimen for previously untreated patients with TCC of the urothelial tract, resulting in a median survival of 20 months. Treatment can be recycled at 3-week intervals without enhanced toxicity. Cancer 2000;88:1671–8. © 2000 American Cancer Society." @default.
- W4255231617 created "2022-05-12" @default.
- W4255231617 creator A5012710313 @default.
- W4255231617 creator A5021307576 @default.
- W4255231617 creator A5036699360 @default.
- W4255231617 creator A5060083492 @default.
- W4255231617 creator A5063435994 @default.
- W4255231617 creator A5064884168 @default.
- W4255231617 creator A5065354635 @default.
- W4255231617 creator A5072850546 @default.
- W4255231617 creator A5076461389 @default.
- W4255231617 creator A5080382920 @default.
- W4255231617 date "2000-04-01" @default.
- W4255231617 modified "2023-10-16" @default.
- W4255231617 title "Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract" @default.
- W4255231617 doi "https://doi.org/10.1002/(sici)1097-0142(20000401)88:7<1671::aid-cncr22>3.3.co;2-1" @default.
- W4255231617 hasPublicationYear "2000" @default.
- W4255231617 type Work @default.
- W4255231617 citedByCount "0" @default.
- W4255231617 crossrefType "journal-article" @default.
- W4255231617 hasAuthorship W4255231617A5012710313 @default.
- W4255231617 hasAuthorship W4255231617A5021307576 @default.
- W4255231617 hasAuthorship W4255231617A5036699360 @default.
- W4255231617 hasAuthorship W4255231617A5060083492 @default.
- W4255231617 hasAuthorship W4255231617A5063435994 @default.
- W4255231617 hasAuthorship W4255231617A5064884168 @default.
- W4255231617 hasAuthorship W4255231617A5065354635 @default.
- W4255231617 hasAuthorship W4255231617A5072850546 @default.
- W4255231617 hasAuthorship W4255231617A5076461389 @default.
- W4255231617 hasAuthorship W4255231617A5080382920 @default.
- W4255231617 hasBestOaLocation W42552316171 @default.
- W4255231617 hasConcept C126189478 @default.
- W4255231617 hasConcept C126322002 @default.
- W4255231617 hasConcept C126894567 @default.
- W4255231617 hasConcept C141071460 @default.
- W4255231617 hasConcept C2776694085 @default.
- W4255231617 hasConcept C2777063308 @default.
- W4255231617 hasConcept C2777506904 @default.
- W4255231617 hasConcept C2778239845 @default.
- W4255231617 hasConcept C2778850193 @default.
- W4255231617 hasConcept C2781413609 @default.
- W4255231617 hasConcept C29730261 @default.
- W4255231617 hasConcept C71924100 @default.
- W4255231617 hasConcept C90924648 @default.
- W4255231617 hasConceptScore W4255231617C126189478 @default.
- W4255231617 hasConceptScore W4255231617C126322002 @default.
- W4255231617 hasConceptScore W4255231617C126894567 @default.
- W4255231617 hasConceptScore W4255231617C141071460 @default.
- W4255231617 hasConceptScore W4255231617C2776694085 @default.
- W4255231617 hasConceptScore W4255231617C2777063308 @default.
- W4255231617 hasConceptScore W4255231617C2777506904 @default.
- W4255231617 hasConceptScore W4255231617C2778239845 @default.
- W4255231617 hasConceptScore W4255231617C2778850193 @default.
- W4255231617 hasConceptScore W4255231617C2781413609 @default.
- W4255231617 hasConceptScore W4255231617C29730261 @default.
- W4255231617 hasConceptScore W4255231617C71924100 @default.
- W4255231617 hasConceptScore W4255231617C90924648 @default.
- W4255231617 hasIssue "7" @default.
- W4255231617 hasLocation W42552316171 @default.
- W4255231617 hasOpenAccess W4255231617 @default.
- W4255231617 hasPrimaryLocation W42552316171 @default.
- W4255231617 hasRelatedWork W136411592 @default.
- W4255231617 hasRelatedWork W2018507611 @default.
- W4255231617 hasRelatedWork W2047108938 @default.
- W4255231617 hasRelatedWork W2061915529 @default.
- W4255231617 hasRelatedWork W2070505874 @default.
- W4255231617 hasRelatedWork W2077567025 @default.
- W4255231617 hasRelatedWork W2106964779 @default.
- W4255231617 hasRelatedWork W2123895550 @default.
- W4255231617 hasRelatedWork W2417967603 @default.
- W4255231617 hasRelatedWork W2807957985 @default.
- W4255231617 hasVolume "88" @default.
- W4255231617 isParatext "false" @default.
- W4255231617 isRetracted "false" @default.
- W4255231617 workType "article" @default.